FDA asks for eye warning on GLP-1 drugs

FDA asks for eye warning on GLP-1 drugs
Ozempic Source: HualinXMN (CC BY-SA / Wikimedia Commons)

On November 9, 2026, the FDA, the United States government office that checks food and medicine, asked for a new warning on GLP-1 drugs. It said these drugs may raise the risk of a rare but serious eye disease called NAION.

FDA asks for eye warning on GLP-1 drugs
Ozempic Source: HualinXMN (CC BY-SA / Wikimedia Commons)

The FDA asked every company that makes GLP-1 drugs to add this risk to the "Warnings and Precautions" part of the label. The drugs include tirzepatide, which is sold as Mounjaro and Zepbound, and semaglutide, which is sold as Ozempic, Rybelsus and Wegovy. Liraglutide, dulaglutide and other drugs are also on the list.

A person with NAION suddenly cannot see well with one eye. The eye does not hurt. Sometimes the eye never gets better. When one eye has the disease, the risk for the other eye also goes up.

The FDA looked at the results of 126 studies together. Among people who took GLP-1 drugs, there were 6.4 cases of NAION for every 100,000 people in one year. Among people who took something else in the studies, there were 3.8 cases. In the general population over 50 years old, there are between 2.3 and 10.2 cases for every 100,000 people each year.

Another study used the FDA's Sentinel system. It compared people taking GLP-1 drugs with people taking two other kinds of medicine. Compared with SGLT-2 inhibitors, the risk was 1.19 times as high, but this difference was too small to be sure. Compared with DPP-4 inhibitors, the risk was 1.43 times as high, and this difference was clear.

Tests on animals did not show how the drugs could cause the disease.

The FDA is asking doctors to send patients to an eye doctor quickly if they may have NAION. If a patient gets the disease, the doctor should think about stopping the drug. The patient should keep taking it only if the good effects are clearly bigger than the risk.

Glossary

  • 313 words
  • 21 sentences
  • 3 mins to read